Steven Brem
YOU?
Author Swipe
View article: IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium
IMG-33. Unveiling glioblastoma heterogeneity with deep learning derived MRI subtyping: insights from the global ReSPOND consortium Open
PURPOSE This study aims to identify distinct imaging subtypes of glioblastoma using multi-modal MRIs from the ReSPOND consortium, providing insights into tumor heterogeneity to inform personalized treatment approaches. METHODS We analyzed …
View article: Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model
Response Assessment in Long-Term Glioblastoma Survivors Using a Multiparametric MRI-Based Prediction Model Open
Purpose: Early treatment response assessments are crucial, and the results are known to better correlate with prognosis and survival outcomes. The present study was conducted to differentiate true progression (TP) from pseudoprogression (P…
View article: Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning-Based Prediction Models to Distinguish Glioblastomas from Single Brain Metastases
Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning-Based Prediction Models to Distinguish Glioblastomas from Single Brain Metastases Open
Background: The accurate and early distinction of glioblastomas (GBMs) from single brain metastases (BMs) provides a window of opportunity for reframing treatment strategies enabling optimal and timely therapeutic interventions. We sought …
View article: Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning Based Prediction Models in Distinguishing Glioblastomas from Single Brain Metastases
Quantitative Physiologic MRI Combined with Feature Engineering for Developing Machine Learning Based Prediction Models in Distinguishing Glioblastomas from Single Brain Metastases Open
Background Accurate and early distinction of glioblastomas (GBMs) from single brain metastases (BMs) provide a window of opportunity for reframing treatment strategies enabling optimal and timely therapeutic interventions. We sought to lev…
View article: The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials
The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials Open
Originally devised for cancer control, mRNA vaccines have risen to the forefront of medicine as effective instruments for control of infectious disease, notably their pivotal role in combating the COVID-19 pandemic. This review focuses on …
View article: Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity
Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity Open
Immuno-oncology, specifically immune checkpoint inhibitors (ICIs), has revolutionized cancer care with dramatic, long-term responses and increased survival, including patients with metastatic cancer to the brain. Glioblastomas, and other p…
View article: Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma
Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma Open
In recent years, the classification of adult-type diffuse gliomas has undergone a revolution, wherein specific molecular features now represent defining diagnostic criteria of IDH-wild-type glioblastomas, IDH-mutant astrocytomas, and IDH-m…
View article: Integrating imaging and genomic data for the discovery of distinct glioblastoma subtypes: a joint learning approach
Integrating imaging and genomic data for the discovery of distinct glioblastoma subtypes: a joint learning approach Open
View article: Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial Open
View article: Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation status
Distinction of pseudoprogression from true progression in glioblastomas using machine learning based on multiparametric magnetic resonance imaging and O6-methylguanine-methyltransferase promoter methylation status Open
Background It is imperative to differentiate true progression (TP) from pseudoprogression (PsP) in glioblastomas (GBMs). We sought to investigate the potential of physiologically sensitive quantitative parameters derived from diffusion and…
View article: CHEX-seq detects single-cell genomic single-stranded DNA with catalytical potential
CHEX-seq detects single-cell genomic single-stranded DNA with catalytical potential Open
View article: CTNI-56. FEASIBILITY AND EFFICACY OF AI-GUIDED PERSONALIZED PRECISION RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: A MATCHED-CONTROL STUDY
CTNI-56. FEASIBILITY AND EFFICACY OF AI-GUIDED PERSONALIZED PRECISION RADIATION THERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA: A MATCHED-CONTROL STUDY Open
PURPOSE The aim of this study was to evaluate the feasibility and efficacy of AI-guided personalized precision radiation therapy (PPRT) in improving outcomes for patients with newly diagnosed glioblastoma. METHODS In an open-label trial co…
View article: NIMG-13. ROBUSTNESS OF PROGNOSTIC STRATIFICATION IN DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: INSIGHTS FROM THE RESPOND CONSORTIUM
NIMG-13. ROBUSTNESS OF PROGNOSTIC STRATIFICATION IN DE NOVO GLIOBLASTOMA PATIENTS ACROSS 22 GEOGRAPHICALLY DISTINCT INSTITUTIONS: INSIGHTS FROM THE RESPOND CONSORTIUM Open
PURPOSE Glioblastoma is the most prevalent primary malignant brain tumor in adults, with a median overall survival (OS) of approximately 15 months and only limited advancements in prognostication and survival prediction. This study aims to…
View article: EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM
EPID-15. SEX-SPECIFIC DIFFERENCES IN GLIOBLASTOMA IN THE RESPOND CONSORTIUM Open
AIM The goal of this study was to understand sex-specific differences in the molecular, clinical and radiological tumor parameters and survival outcomes of Glioblastoma (GBM) patients within the international GBM dataset, known as the ReSP…
View article: NIMG-39. BENCHMARKING MULTI-LABEL PREDICTION OF TARGET GENE MUTATION STATUS IN GLIOBLASTOMA USING RADIOGENOMICS AND MULTI-PARAMETRIC MR IMAGING
NIMG-39. BENCHMARKING MULTI-LABEL PREDICTION OF TARGET GENE MUTATION STATUS IN GLIOBLASTOMA USING RADIOGENOMICS AND MULTI-PARAMETRIC MR IMAGING Open
PURPOSE In vivo imaging-based prediction of gene mutation status can significantly contribute to the diagnosis and treatment of glioblastoma. Radiogenomics provides a non-invasive approach to capturing the phenotypical characteristics of m…
View article: NIMG-66. RADIOGENOMICS-BASED HETEROGENEITY ANALYSIS OF GLIOBLASTOMA REVEALS MR IMAGING PHENOTYPICAL CHARACTERIZATION OF EGFR MUTATIONS
NIMG-66. RADIOGENOMICS-BASED HETEROGENEITY ANALYSIS OF GLIOBLASTOMA REVEALS MR IMAGING PHENOTYPICAL CHARACTERIZATION OF EGFR MUTATIONS Open
PURPOSE EGFR is one of the most frequently altered genes in glioblastoma, while also being an attractive therapeutic target for treatment. Having in vivo, imaging-based markers of EGFR mutations, and as well as characterizing molecular het…
View article: CTIM-24. REPEATED PERIPHERAL INFUSIONS OF ANTI-EGFRVIII CAR T CELLS IN COMBINATION WITH PEMBROLIZUMAB REMODELS THE TUMOR MICROENVIRONMENT IN DE NOVO GLIOBLASTOMA
CTIM-24. REPEATED PERIPHERAL INFUSIONS OF ANTI-EGFRVIII CAR T CELLS IN COMBINATION WITH PEMBROLIZUMAB REMODELS THE TUMOR MICROENVIRONMENT IN DE NOVO GLIOBLASTOMA Open
Treatment efficacy with chimeric antigen receptor (CAR) T cell therapy in glioblastoma (GBM) is undermined by an immunosuppressive tumor microenvironment (TME). We previously showed that CAR T cell therapy targeting epidermal growth factor…
View article: CTNI-52. SURVIVAL OUTCOMES IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS TREATED WITH A SINGLE INTRA-TUMORAL ADMINISTRATION OF BIZAXOFUSP, AN IL-4R-TARGETING TOXIN, IN A PHASE IIB TRIAL
CTNI-52. SURVIVAL OUTCOMES IN RECURRENT GLIOBLASTOMA (RGBM) PATIENTS TREATED WITH A SINGLE INTRA-TUMORAL ADMINISTRATION OF BIZAXOFUSP, AN IL-4R-TARGETING TOXIN, IN A PHASE IIB TRIAL Open
BACKGROUND Bizaxofusp (MDNA55) is an IL4R-targeting toxin in development for recurrent (r)GBM, a universally fatal disease with mOS of 6-9 months. IL-4R is overexpressed in GBM and surrounding tumor microenvironment, with high expression a…
View article: EPCO-26. INTRATUMORAL HETEROGENEITY OF GBM IDENTIFIED AND CHARACTERIZED BY A MULTISAMPLING APPROACH AND METHYLATION PROFILING
EPCO-26. INTRATUMORAL HETEROGENEITY OF GBM IDENTIFIED AND CHARACTERIZED BY A MULTISAMPLING APPROACH AND METHYLATION PROFILING Open
Intratumoral heterogeneity in glioblastoma is known and is considered a key feature of GBM’s clinical aggressiveness. To more fully characterize this phenomenon, we conducted methylation profiling on the EPIC array for 79 regions from 20 g…
View article: GLIOMA-06 THE GLIOMA CONNECTOME PROJECT – UPDATE
GLIOMA-06 THE GLIOMA CONNECTOME PROJECT – UPDATE Open
The ability to define specific fiber tracts in individual patients before, during and following surgery represents a major advance in neurosurgical oncology. The Human Connectome Project (Glasser, 2016) generated insights into the organiza…
View article: GLIOMA-05 A NOVEL CONCEPT FOR TREATMENT OF GLIOBLASTOMA: VAGUS NERVE ELECTRICAL STIMULATION FOR SUPPRESSION OF CYTOKINE (IL-6) SIGNALING
GLIOMA-05 A NOVEL CONCEPT FOR TREATMENT OF GLIOBLASTOMA: VAGUS NERVE ELECTRICAL STIMULATION FOR SUPPRESSION OF CYTOKINE (IL-6) SIGNALING Open
Glioblastoma is an aggressive, incurable cancer. Innovative approaches are urgently needed. There is resurgent interest in harnessing the power of the immune system (O’Rourke DM, 2017; Liau LM, 2023). Glioblastoma is a key target for cytok…
View article: TRANSLATIONAL RESEARCH-02 THE KEYSTONE CYTOKINE, INTERLEUKIN-6, A KEY TARGET AND “ORGANIZING PRINCIPLE” FOR GLIOBLASTOMA THERAPY: A DECADE OF TRANSLATIONAL PROGRESS FROM GENOMICS TO THE LABORATORY AND TO A MULTICENTER CLINICAL TRIAL
TRANSLATIONAL RESEARCH-02 THE KEYSTONE CYTOKINE, INTERLEUKIN-6, A KEY TARGET AND “ORGANIZING PRINCIPLE” FOR GLIOBLASTOMA THERAPY: A DECADE OF TRANSLATIONAL PROGRESS FROM GENOMICS TO THE LABORATORY AND TO A MULTICENTER CLINICAL TRIAL Open
Interleukin-6 (IL-6), the ‘keystone cytokine’, affects homeostatic processes, including innate and adaptive immunity, and is regarded as a prominent target for clinical intervention (Hunter, 2015). IL-6 is also a senescence-associated-gene…
View article: P17.04.B A PHASE 2 STUDY OF NIRAPARIB CONCOMITANT WITH TUMOR TREATING FIELDS (TTFIELDS) IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG)
P17.04.B A PHASE 2 STUDY OF NIRAPARIB CONCOMITANT WITH TUMOR TREATING FIELDS (TTFIELDS) IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA (HGG) Open
BACKGROUND Preclinical data have demonstrated that application of TTFields reduces gene expression within the FA-BRCA DNA-damage response pathway, thus inducing potential sensitivity to PARP inhibition. We conducted a phase 2 trial of TTFi…
View article: JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL
JS09.5.A18F-FLUCICLOVINE PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: IMAGE INTERPRETATION CRITERIA RESULTS FROM PURSUE, A PROSPECTIVE PHASE 2 TRIAL Open
BACKGROUND Differentiating radiation necrosis from tumour progression after radiation therapy (RT) for brain metastases (BM) remains clinically challenging, and accurate imaging is crucial to prevent unnecessary surgery or unwarranted chan…
View article: NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY
NEIM-05 PURSUE: RESULTS FROM A PROSPECTIVE, PHASE 2B TRIAL TO DEFINE IMAGE INTERPRETATION CRITERIA FOR18F-FLUCICLOVINE-PET FOR DETECTION OF RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY Open
BACKGROUND After radiation therapy (RT) for brain metastases (BM), differentiating radiation necrosis from tumor recurrence remains challenging. PURSUE (NCT04410367) evaluated various measures of lesion 18F-fluciclovine uptake to establish…
View article: Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium
Association of partial T2-FLAIR mismatch sign and isocitrate dehydrogenase mutation in WHO grade 4 gliomas: results from the ReSPOND consortium Open
Partial T2-FLAIR mismatch sign is highly specific for IDH mutation in WHO grade 4 gliomas.
View article: CrOssing fiber Modeling in the Peritumoral Area using dMRI (COMPARI)
CrOssing fiber Modeling in the Peritumoral Area using dMRI (COMPARI) Open
Visualization of fiber tracts around the tumor is critical for neurosurgical planning and preservation of crucial structural connectivity during tumor resection. Biophysical modeling approaches estimate fiber tract orientations from differ…
View article: Supplementary Figures 1-9, Supplementary Tables 1-3 from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability
Supplementary Figures 1-9, Supplementary Tables 1-3 from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability Open
S1: Raw bioluminescence data obtained from screens of kinase, protease, and redox inhibitors. S2: Bioluminescent and viability data from U251 DR5 Luciferase cells treated with an NH125 dilution series. S3: Representative images of T4213 ne…
View article: Supplementary Figures 1-9, Supplementary Tables 1-3 from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability
Supplementary Figures 1-9, Supplementary Tables 1-3 from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability Open
S1: Raw bioluminescence data obtained from screens of kinase, protease, and redox inhibitors. S2: Bioluminescent and viability data from U251 DR5 Luciferase cells treated with an NH125 dilution series. S3: Representative images of T4213 ne…
View article: Data from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability
Data from An Integrated Stress Response Agent that Modulates DR5-Dependent TRAIL Synergy Reduces Patient-Derived Glioma Stem Cell Viability Open
The high incidence of glioblastoma recurrence necessitates additional therapeutic strategies. Heterogeneous populations of cells, including glioma stem cells (GSC) have been implicated in disease recurrence. GSCs are able to survive irradi…